Aktienanalyse zu Medpace Holdings Inc (MEDP)MEDPMedpace Holdings Inc

Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company's drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company's operations are principally based in North America, Europe, and Asia. It operates in the Healthcare sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).

Medpace Holdings Inc is a good buy right now due to its current price of $618.47, which is below the analyst price target of $700 from Mizuho, indicating a potential upside of approximately 13%. Additionally, the company has shown strong financial performance with a gross margin of 27.56% in Q2 2026 and a forward P/E ratio of 31.95, suggesting that the stock is reasonably valued considering its growth prospects. The main risk is the recent insider selling by the CEO, who sold 15,978 shares, which could raise concerns among investors, but he still retains a significant stake in the company.

7 analysts cover MEDP: 1 rate it Buy, 6 Hold and 0 Sell. The average price target is 569.17.